Moreover, upregulated expression of SYNJ2 represented unfavorable disease free interval (DFI) and progression free interval (PFI) for patients with adrenocortical carcinoma (ACC) and LUAD (HR > 1, p < 0.05; Fig. 7A–D); it also served as a risk factor for PFI of patients with GBM, LGG, LIHC, LUSC, pheochromocytoma and paraganglioma (PCPG), and UVM (HR > 1, p < 0.05; Fig. 7B, D). This evidence concerns the gene SYNJ2 and adrenal cortex carcinoma.